160 related articles for article (PubMed ID: 37083881)
1. The intra-tumoral heterogeneity in glioblastoma - a limitation for prognostic value of epigenetic markers?
Christoph S; Alicia S; Fritz T; Vanessa T; Ralf K; Jin KY; Stefan L; Joachim O
Acta Neurochir (Wien); 2023 Jun; 165(6):1635-1644. PubMed ID: 37083881
[TBL] [Abstract][Full Text] [Related]
2. The Influence of Distinct Regulatory miRNAs of the p15/p16/RB1/E2F Pathway on the Clinical Progression of Glioblastoma Multiforme.
Sippl C; Teping F; Ketter R; Braun L; Tremmel L; Schulz-Schaeffer W; Oertel J; Urbschat S
World Neurosurg; 2019 Dec; 132():e900-e908. PubMed ID: 31351207
[TBL] [Abstract][Full Text] [Related]
3. miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme.
Sippl C; Ketter R; Braun L; Teping F; Schoeneberger L; Kim YJ; List M; Nakhoda A; Wemmert S; Oertel J; Urbschat S
Acta Neurochir (Wien); 2019 Nov; 161(11):2299-2309. PubMed ID: 31478117
[TBL] [Abstract][Full Text] [Related]
4. miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma.
Khalil S; Fabbri E; Santangelo A; Bezzerri V; Cantù C; Di Gennaro G; Finotti A; Ghimenton C; Eccher A; Dechecchi M; Scarpa A; Hirshman B; Chen C; Ferracin M; Negrini M; Gambari R; Cabrini G
Oncotarget; 2016 May; 7(19):28195-206. PubMed ID: 27057640
[TBL] [Abstract][Full Text] [Related]
5. microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide.
Lizarte Neto FS; Rodrigues AR; Trevisan FA; de Assis Cirino ML; Matias CCMS; Pereira-da-Silva G; Peria FM; Tirapelli DPDC; Carlotti CG
Brain Res; 2019 Oct; 1720():146302. PubMed ID: 31226325
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients.
Chen YY; Ho HL; Lin SC; Ho TD; Hsu CY
Am J Clin Pathol; 2018 Mar; 149(5):412-417. PubMed ID: 29538610
[TBL] [Abstract][Full Text] [Related]
7. Integrative analysis of DNA methylation and gene expression to identify key epigenetic genes in glioblastoma.
Jia D; Lin W; Tang H; Cheng Y; Xu K; He Y; Geng W; Dai Q
Aging (Albany NY); 2019 Aug; 11(15):5579-5592. PubMed ID: 31395792
[TBL] [Abstract][Full Text] [Related]
8. MiRNA-181d Expression Significantly Affects Treatment Responses to Carmustine Wafer Implantation.
Sippl C; Ketter R; Bohr L; Kim YJ; List M; Oertel J; Urbschat S
Neurosurgery; 2019 Jul; 85(1):147-155. PubMed ID: 29846701
[TBL] [Abstract][Full Text] [Related]
9. MiRNA-181d Expression Correlates in Tumor versus Plasma of Glioblastoma Patients-the Base of a Preoperative Stratification Tool for Local Carmustine Wafer Use.
Sippl C; Quiring A; Teping F; Schulz-Schaeffer W; Urbschat S; Ketter R; Oertel J
World Neurosurg; 2022 Mar; 159():e324-e333. PubMed ID: 34942386
[TBL] [Abstract][Full Text] [Related]
10. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
11. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
Bady P; Sciuscio D; Diserens AC; Bloch J; van den Bent MJ; Marosi C; Dietrich PY; Weller M; Mariani L; Heppner FL; Mcdonald DR; Lacombe D; Stupp R; Delorenzi M; Hegi ME
Acta Neuropathol; 2012 Oct; 124(4):547-60. PubMed ID: 22810491
[TBL] [Abstract][Full Text] [Related]
12. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
13. Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma.
Preusser M; Berghoff AS; Manzl C; Filipits M; Weinhäusel A; Pulverer W; Dieckmann K; Widhalm G; Wöhrer A; Knosp E; Marosi C; Hainfellner JA
Clin Neuropathol; 2014; 33(1):6-14. PubMed ID: 24359605
[TBL] [Abstract][Full Text] [Related]
14. A 4-miRNAs signature predicts survival in glioblastoma multiforme patients.
Yuan GQ; Wei NL; Mu LY; Wang XQ; Zhang YN; Zhou WN; Pan YW
Cancer Biomark; 2017 Dec; 20(4):443-452. PubMed ID: 28869437
[TBL] [Abstract][Full Text] [Related]
15. A five-CpG signature of microRNA methylation in non-G-CIMP glioblastoma.
Kang EM; Yin AA; He YL; Chen WJ; Etcheverry A; Aubry M; Barnholtz-Sloan J; Mosser J; Zhang W; Zhang X
CNS Neurosci Ther; 2019 Sep; 25(9):937-950. PubMed ID: 31016891
[TBL] [Abstract][Full Text] [Related]
16. Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas.
Ramakrishnan V; Kushwaha D; Koay DC; Reddy H; Mao Y; Zhou L; Ng K; Zinn P; Carter B; Chen CC
Cancer Biomark; 2011-2012; 10(3-4):185-93. PubMed ID: 22674304
[TBL] [Abstract][Full Text] [Related]
17. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
[TBL] [Abstract][Full Text] [Related]
19. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression.
Zhang W; Zhang J; Hoadley K; Kushwaha D; Ramakrishnan V; Li S; Kang C; You Y; Jiang C; Song SW; Jiang T; Chen CC
Neuro Oncol; 2012 Jun; 14(6):712-9. PubMed ID: 22570426
[TBL] [Abstract][Full Text] [Related]
20. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.
Shu C; Wang Q; Yan X; Wang J
Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
